Revenue
2019
2020
2021
2022
2023
2024
2025
Keros Therapeutics, Inc. (KROS)
Price$11.32Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $244.1M | $3.5M | $151,000 | $0 | $20.1M | $0 | $10.0M |
| Research & development | $129.6M | $173.6M | $135.3M | $87.3M | $55.1M | $33.9M | $17.4M |
| Operating expenses | $176.5M | $214.4M | $170.1M | $114.8M | $76.5M | $46.7M | $20.6M |
| Operating income | $67.6M | −$210.8M | −$169.9M | −$114.8M | −$56.4M | −$46.7M | −$10.6M |
| Operating margin | 27.69% | −5,938.96% | −112,543.71% | — | −280.46% | — | −105.63% |
| EBITDA | $69.1M | −$209.6M | −$169.1M | −$114.1M | −$56.0M | −$46.4M | −$10.4M |
| EBITDA margin | 28.30% | −5,904.34% | −112,003.97% | — | −278.58% | — | −103.55% |
| Net income | $87.0M | −$187.4M | −$153.0M | −$104.7M | −$58.7M | −$45.4M | −$12.3M |
| Net profit margin | 35.65% | −5,277.55% | −101,319.21% | — | −292.26% | — | −123.36% |
| Basic EPSper basic share | $2.34 | -$5.00 | -$5.20 | -$4.15 | -$2.52 | -$2.93 | -$6.08 |
| Diluted EPSper diluted share | $2.30 | -$5.00 | -$5.20 | -$4.15 | -$2.52 | -$2.93 | -$6.08 |
Owners
Reported shareholders
14.23%of listed shares
Nantahala Capital Management, LLC2.82M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Nantahala Capital Management, LLC | 14.23%2.82M shares |
BlackRock, Inc. | 14.09%2.79M shares |
AQR CAPITAL MANAGEMENT LLC | 4.88%967.86K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.20%833.6K shares |
GORDON CARL L | ≈4.06%804.21K shares |
ORBIMED ADVISORS LLC | 3.83%759.16K shares |
FEDERATED HERMES, INC. | 3.53%700.43K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.29%652.64K shares |
MACKENZIE FINANCIAL CORP | 3.17%628.44K shares |
Madison Avenue Partners, LP | 3.16%626.58K shares |
Qube Research & Technologies Ltd | 3.07%608.84K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3.05%605.45K shares |
STATE STREET CORP | 2.73%541.19K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.58%510.84K shares |
DIMENSIONAL FUND ADVISORS LP | 2.32%460.54K shares |
Seehra Jasbir | ≈2.22%440.71K shares |
CITADEL ADVISORS LLC | 2.00%396.1K shares |
RENAISSANCE TECHNOLOGIES LLC | 1.81%359.09K shares |
D. E. Shaw & Co., Inc. | 1.35%267.46K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.34%265.02K shares |
Percentages use 19.83M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 · 10b5-1 | BIENAIME JEAN JACQUESDirector | BuyCommon Stock | 1.0K | $10.19 | $10.2K | 17.6K |
| Jun 11, 2026Form 4 · 10b5-1 | Newton Charles W.Director | SellCommon Stock | 550 | $10.04 | $5.5K | 12.7K |
| Jun 4, 2026Form 4 · 10b5-1 | Knowles JuliusDirector | SellCommon Stock | 2.6K | $10.73 | $28.2K | 11.0K |
| Jun 4, 2026Form 4 · 10b5-1 | Farzan NimaDirector | SellCommon Stock | 2.6K | $10.73 | $28.2K | 9.8K |
| Jun 4, 2026Form 4 · 10b5-1 | Seth AlpnaDirector | SellCommon Stock | 2.6K | $10.72 | $28.1K | 9.8K |